ALK-Positive NSCLC: Adjuvant Alectinib vs Platinum-Based Chemotherapy
The phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy in patients with resected ALK-positive NSCLC.